On the stock market since 1999, it operates in the world of health and science. It has 2,300 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
An average decline of 24% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 79% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The company sells $588.0M a year; the problem isn’t sales — it’s costs running above that number.
There is $446.6M in the vault; even if every debt were paid off, $227.2M would remain.
Over the last 12 months, company executives reported 19 buys and 9 sells. Management buying with its own money is usually read as a good sign.
A loss of $86.5M against $588.0M in annual sales.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
The sales tempo runs behind the sector. Council score: 4/10.
On our five-subject report card, MDRX sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: MDRX has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.